background
respiratori
syncyti
viru
rsv
infect
result
signific
morbid
mortal
immunocompromis
patient
optim
manag
strategi
unknown
practic
vari
wide
center
sought
assess
practic
variat
larg
transplant
center
particip
midwest
respiratori
viru
consortium
mrvc
method
survey
assess
center
characterist
treatment
strategi
sent
transplant
infecti
diseas
tid
physician
particip
center
addit
inform
regard
treatment
noninfluenza
nonrsv
respiratori
viral
infect
obtain
result
center
respond
multiplex
polymeras
chain
reaction
pcr
use
diagnosi
center
one
center
use
rapid
antigen
test
institut
use
inhal
ribavirin
rbv
least
patient
popul
reason
cite
barrier
use
includ
cost
safeti
lack
support
evid
inconveni
center
use
oral
rbv
state
specif
prefer
oral
prefer
inhal
use
intraven
immunoglobulin
ivig
often
combin
rbv
poststem
cell
transplant
sct
popul
patient
lower
respiratori
tract
infect
lrti
like
treat
upper
respiratori
tract
infect
urti
preengraft
allosct
recipi
urti
would
receiv
rbv
center
lrti
would
treat
rbv
center
center
perform
lung
transplant
use
either
oral
inhal
rbv
lrti
urti
center
routin
treat
nonlung
solid
organ
transplant
sot
recipi
urti
would
consid
oral
inh
rbv
group
lrti
patient
hematolog
malign
hsct
treat
rbv
similar
frequenc
urti
lrti
center
sever
case
treat
parainfluenza
metapneumoviru
coronaviru
ivig
rbv
conclus
treatment
rsv
immunocompromis
patient
vari
greatli
institut
presenc
heterogen
demonstr
need
studi
defin
optim
treatment
rsv
immunocompromis
host
disclosur
author
report
disclosur
